Vertex Pharmaceuticals (VX1D) Stock Overview

Operates as a biotechnology company in the United States, Europe, and internationally. More details

VX1D fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 46.2% below our estimate of its fair value

Earnings are forecast to grow 13.01% per year

Became profitable this year

Analysts in good agreement that stock price will rise by 23.1%

Risk Analysis

VX1D passed our risk checks.

VX1D Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Vertex Pharmaceuticals Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vertex Pharmaceuticals
Historical stock prices
Current Share Price	US$384.10
52 Week High	US$341.15
52 Week Low	US$322.40
Beta	0.31
1 Month Change	5.59%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	24.65%
5 Year Change	n/a
Change since IPO	38.34%

Recent updates

Shareholder Returns

	VX1D	GB Biotechs	GB Market
7D	4.6%	-3.4%	-1.9%
1Y	n/a	13.2%	14.9%

Return vs Industry: Insufficient data to determine how VX1D performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how VX1D performed against the UK Market.

Price Volatility

Is VX1D's price volatile compared to industry and market?
VX1D volatility
VX1D Average Weekly Movement	5.8%
Biotechs Industry Average Movement	8.5%
Market Average Movement	5.6%
10% most volatile stocks in GB Market	11.6%
10% least volatile stocks in GB Market	3.1%

Stable Share Price: VX1D has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine VX1D's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1989	6,400	Reshma Kewalramani	www.vrtx.com

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.

Vertex Pharmaceuticals Incorporated Fundamentals Summary

How do Vertex Pharmaceuticals's earnings and revenue compare to its market cap?
VX1D fundamental statistics
Market cap	€97.39b
Earnings (TTM)	€3.76b
Revenue (TTM)	€10.58b

26.1x

P/E Ratio

9.3x

P/S Ratio

Is VX1D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VX1D income statement (TTM)
Revenue	US$12.22b
Cost of Revenue	US$5.57b
Gross Profit	US$6.65b
Other Expenses	US$2.31b
Earnings	US$4.34b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	17.09
Gross Margin	54.39%
Net Profit Margin	35.51%
Debt/Equity Ratio	0%

How did VX1D perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/09 12:56
End of Day Share Price	2026/06/09 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vertex Pharmaceuticals Incorporated is covered by 58 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
Eliana Merle	Barclays

Vertex Pharmaceuticals (VX1D) Stock Overview

Rewards

Risk Analysis

Vertex Pharmaceuticals Incorporated Competitors

Genus

GSK

AstraZeneca

Haleon

Price History & Performance

Recent News & Updates

Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals Announces New Drug Submission for Suzetrigine Accepted for Review by Health Canada

Vertex Pharmaceuticals Incorporated Reaffirms Earnings Guidance for Full Year 2026

Vertex Pharmaceuticals Incorporated to Report Q1, 2026 Results on May 04, 2026

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 13, 2026

Recent updates

Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals Announces New Drug Submission for Suzetrigine Accepted for Review by Health Canada

Vertex Pharmaceuticals Incorporated Reaffirms Earnings Guidance for Full Year 2026

Vertex Pharmaceuticals Incorporated to Report Q1, 2026 Results on May 04, 2026

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 13, 2026

Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval of Expanded Use of ALYFTREK (Vanzacaftor/Tezacaftor/Ivacaftor)

Vertex Pharmaceuticals Incorporated Announces Positive Interim Analysis Results for Povetacicept in Rainier Phase 3 Trial

Vertex Pharmaceuticals Incorporated Presents New Data on JOURNAVX for Effective Pain Management Following Aesthetic and Reconstructive Procedures

Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Full Year 2026

Vertex Pharmaceuticals Incorporated to Report Q4, 2025 Results on Feb 12, 2026

Vertex Pharmaceuticals Incorporated Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Vertex Pharmaceuticals Incorporated Updates Earnings Guidance for the Fiscal Year 2025

Vertex Pharmaceuticals Incorporated Announces Progress in Povetacicept Development Program

Vertex Pharmaceuticals Incorporated to Report Q3, 2025 Results on Nov 03, 2025

Vertex Pharmaceuticals Incorporated Announces Key Advancements Across Kidney Portfolio

Vertex Pharmaceuticals Incorporated Announces Chief Scientific Officer Changes

Vertex Pharmaceuticals Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Announces Broad Reimbursement Agreement with NHS England for ALYFTREK®? an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated to Report Q2, 2025 Results on Aug 04, 2025

Vertex Pharmaceuticals Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY®? and Provides Update on Expanding Global Access to CASGEVY

Vertex Pharmaceuticals Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell Top 200 Value Index

Vertex Pharmaceuticals Incorporated Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full-Year 2025

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom

Vertex Pharmaceuticals Incorporated to Report Q1, 2025 Results on May 05, 2025

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 14, 2025

Vertex Pharmaceuticals Incorporated Announces Program Updates for Type 1 Diabetes Portfolio

Vertex Pharmaceuticals Announces UK MHRA Approval of ALYFTREK®?

Vertex Pharmaceuticals Incorporated Executive Changes

Vertex Pharmaceuticals Incorporated Announces FDA Approval of Journavx (Suzetrigine), A First-In-Class Treatment for Adults with Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2024 Results on Feb 10, 2025

Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants

Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy

Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023)

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Shareholder Returns

Price Volatility